Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC) is a type of cancer that arises from the squamous cells lining the esophagus, often leading to symptoms such as difficulty swallowing, weight loss, and chest pain.
Esophageal Cancer: Ifinatamab Deruxtecan Study
We are studying Ifinatamab Deruxtecan in patients with advanced esophageal squamous cell carcinoma who have already been treated. The goal is to see if it works better than standard chemotherapy options.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Do you have esophageal squamous cell carcinoma (ESCC) that cannot be surgically removed?
- Have you had any major lung problems, like severe asthma or COPD, that affect your breathing?
- Are you currently taking steroids like prednisone at a dose of 10 mg or more each day?
- Have you had any serious blood clots or strokes in the past 6 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ifinatamab Deruxtecan
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Abutrax
Apexelsin
Axitaxel
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Oncology
Heverlee, Belgium
Universitair Ziekenhuis Gent
Oncology
Ledeberg, Belgium
Institut Jules Bordet
Oncology
Negenmanneke, Belgium
Sponsor: Daiichi Sankyo Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.